# Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer

> **NCT01776008** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 16 (actual)

## Conditions studied

- Estrogen Receptor Positive
- HER2/Neu Negative
- Recurrent Breast Carcinoma
- Stage IIA Breast Cancer
- Stage IIB Breast Cancer
- Stage IIIA Breast Cancer
- Stage IIIB Breast Cancer
- Stage IIIC Breast Cancer

## Interventions

- **DRUG:** Akt Inhibitor MK2206
- **DRUG:** Anastrozole
- **DRUG:** Goserelin Acetate
- **OTHER:** Laboratory Biomarker Analysis
- **PROCEDURE:** Neoadjuvant Therapy
- **OTHER:** Pharmacological Study
- **PROCEDURE:** Therapeutic Conventional Surgery

## Key facts

- **NCT ID:** NCT01776008
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-01
- **Primary completion:** 2015-05
- **Final completion:** 2015-05-05
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Study did not pass Stage 1 interim analysis.
- **Last updated:** 2018-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01776008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01776008, "Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01776008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*